Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the extremity, a randomized trial showed. In patients with mostly undifferentiated ...

A phase II study of an oncolytic herpes simplex virus 2 and an anti-PD-1 antibody in patients with advanced sarcoma. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...

Anlotinib combined with chemotherapy showed a 30.8% ORR and 82.7% DCR in advanced STS patients, indicating promising efficacy. The study involved 52 patients with high-grade STS, with a median ...

Patients with non-metastatic soft tissue sarcoma (STS) who need pre-operative radiation therapy can safely receive hypofractionated treatment over three weeks instead of five, with comparable tumor ...

Results presented here showed negative pressure wound therapy is a safe adjunct for soft tissue sarcoma treated with ...

This article first appeared with Targeted Oncology ™. An orphan drug designation (ODD) was granted by the FDA to elraglusib for the treatment of patients with soft tissue sarcoma (STS). 1 Currently, a ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — A novel T-cell receptor therapy showed promising antitumor activity in patients with advanced soft ...

One expert from the University of Colorado Cancer Center explains the multidisciplinary aspect of sarcoma care to maximize patients’ functioning. Treating patients with soft tissue sarcoma or bone ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results ...

Investigators from Cedars-Sinai Cancer have discovered that cancerous tumors called soft-tissue sarcomas produce a protein that switches immune cells from tumor-attacking to tumor-promoting. The study ...

A novel intratumoral treatment was administered to the first patient in a phase 3 trial for certain patients with metastatic soft tissue sarcoma. A phase 3 trial for patients with metastatic soft ...